Reemq Kashif

Dr. Reemq Kashif

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Pediatric Transplantation
Verified
Journal Article
Closed access
RKReemq Kashif
Reemq Kashif
BHBiljana Horn
Biljana Horn
JMJordan Milner
Jordan Milner
MJMichael Joyce
Michael Joyce
MDMansi Dalal
Mansi Dalal
DCDeepak Chellapandian
Deepak Chellapandian

27 March 2025 in Genes
Verified
Journal Article
Open access
PDF file
PMPatrick Maher
Patrick Maher
EGEmilia Guzman
Emilia Guzman
JCJoanna Chaffin
Joanna Chaffin
RKReemq Kashif
Reemq Kashif
RBRachel D Burnside
Rachel D Burnside
Background/Objective: Epstein-Barr Virus (EBV) infection can be associated with lymphocytic hematological malignancies, including systemic Epstein-Barr virus-positive T-cell lymphoma of childhood (SEBVTCL). A common complication of EBV infection, hemophagocytic lymphohistiocytosis (HLH), is a life-threatening condition of immune activation present in virtually all cases of SEBVTCL that requires urgent treatment, as this malignancy can be rapidly fatal. Abnormal karyotypes have been strongly associated with SEBVTCL as a distinguishing feature from HLH in the literature. Here, we discuss the diagnostic challenges and social complications in the case of an unaccompanied minor immigrant patient with a highly complex karyotype diagnosed with SEBVTCL with associated HLH. Methods: Laboratory testing confirmed the presence of EBV+ HLH and cytogenetic analysis was performed to investigate a neoplastic process in this patient, confirming SEBVTCL. Chromosomal microarray (CMA) was performed to try to clarify the complex findings by chromosome analysis but demonstrated normal results. Results: Chromosome analysis demonstrated a highly complex hypertriploid clone that confirmed the diagnosis of SEBVTCL. After declining treatment, the patient was discharged to his guardian against medical advice and succumbed to his disease shortly after. Conclusions: SEBVTCL can be challenging to diagnose due to the similarity in clinical and pathological presentations. In virtually all cases reported in the literature, an abnormal karyotype has been reported to be the most important prognostic factor. We propose that in cases with diagnostic ambiguity, an abnormal karyotype can help favor SEBVTCL over EBV+ HLH.

Verified
Journal Article
Open access
PDF file
JOJohn O Ogunbileje
John O Ogunbileje
NHNeil Harris
Neil Harris
TWTung Wynn
Tung Wynn
RKReemq Kashif
Reemq Kashif
BSBrian Stover
Brian Stover
BOBremansu OSA-ANDREWS
Bremansu OSA-ANDREWS
The ATP-binding cassette (ABC) transporters are a vast group of 48 membrane proteins, some of which are of notable physiological and clinical importance. Some ABC transporters are involved in functions such as the transport of chloride ions, bilirubin, reproductive hormones, cholesterol, and iron. Consequently, genetic or physiological disruption in these functions is manifested in various disease processes like cystic fibrosis, Tangier disease, and sideroblastic anemia. Among other etiologies, primary sideroblastic anemia results from a genetic mutation in the ATP-binding cassette-7 (ABCB7), a member of the ABC transporter family. There are not many articles specifically tackling the disease processes caused by ABC transporters in detail. Some testing methodologies previously reported in the available literature for investigating sideroblastic anemia need updating. Here, we expound on the relevance of ABCB7 as a clinically important ABC transporter and a rare participant in the disease process of Sideroblastic anemia. The other genetic and secondary etiologies of sideroblastic anemia, which do not involve mutations in the ABCB7 protein, are also described. We review the pathophysiology, clinical course, symptoms, diagnosis, and treatment of sideroblastic anemia with a focus on modern technologies for laboratory testing.

4 April 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
RKReemq Kashif
Reemq Kashif
TWTanya Wallace‐Farquharson
Tanya Wallace‐Farquharson
CACandice Adams‐Mitchell
Candice Adams‐Mitchell
YYYingwei Yao
Yingwei Yao
RMRobert E. Molokie
Robert E. Molokie
AMA. Kyle Mack
A. Kyle Mack
Background: This study aimed to validate a Composite Pain Index (CPI) as a single pain outcome measure for sickle cell disease (SCD) across the lifespan from 8 years of age.Procedure: This prospective, cross‐sectional study included 55 participants with SCD who completed the PAINReportIt tool and Adolescent Pediatric Pain Tool (APPT) in random order during outpatient visits to derive respective CPI scores for comparison.Results: Of the 55 participants with SCD, 46 (84%) had HgbSS, eight (15%) HgbSC, and one (2%) HgbSβ0+. The mean age of all participants was 17.5 ± 2.6 years, and 28 (51%) were female, 52 (95%) were Black, 42 (98%) were non‐Hispanic, and 39 (71%) had a ninth grade or higher education. Correlation analyses between the APPT and PAINReportIt revealed positive associations for the number of pain sites (r = .57, p < .001), pain intensity (r = .46, p < .001), pain quality (r = .74, p < .001), and pain pattern (r = .34, p = .01). Patients’ mean CPI scores derived from the PAINReportIt was slightly higher than the APPT; 34.2 (SD = 14.7) and 30.0 (SD = 19.0), respectively. Regression analyses showed that the APPT CPI significantly predicted the PAINReportIt CPI (B = .497, t(53) = 6.051, p < .001). This finding holds true even when accounting for the order of measurement or patient's age.Conclusion: The initial validation of CPI as a single pain outcome measure represents a significant advancement in pain assessment for SCD. Further validation is warranted for the CPI as a measure is for both clinicians and researchers to enable longitudinal pain assessment from age 8 years across the lifespan as children age into adult care.

28 December 2024 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
BFBrian Fazzone
Brian Fazzone
RKReemq Kashif
Reemq Kashif
DNDan Neal
Dan Neal
RRRachel Raymond
Rachel Raymond
MBMarie T. Berg
Marie T. Berg
SRSteven Raymond
Steven Raymond

20 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PMPatrick Maher
Patrick Maher
EGEmilia Guzman
Emilia Guzman
JCJoanna Chaffin
Joanna Chaffin
RKReemq Kashif
Reemq Kashif
RBRachel D Burnside
Rachel D Burnside
Background/Objective Epstein-Barr Virus (EBV) infection can be associated with lymphocytic hematological malignancies, including Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood (SEBVTCL). A common complication of EBV infection, hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition of immune activation that is present in virtually all cases of SEBVTCL, which requires urgent treatment as this malignancy can be rapidly fatal. Abnormal karyotypes have been strongly associated with SEBVTCL as a distinguishing feature from HLH in the literature. Here, we discuss the diagnostic challenges and social complications in a case of an unaccompanied minor immigrant patient with a highly complex karyotype diagnosed with SEBVTCL with associated HLH. Methods Laboratory testing confirmed the presence of EBV+ HLH and cytogenetic analysis was performed to investigate a neoplastic process in this patient, confirming SEBVTCL. Chromosomal microarray (CMA) was performed to try to clarify the complex findings by chromosome analysis but demonstrated normal results. Results: Chromosome analysis demonstrated a highly complex hypertriploid clone that confirmed a diagnosis SEBVTCL. After declining treatment, the patient was discharged to his guardian against medical advice and succumbed to his disease shortly after. Conclusions: SEBVTCL can be challenging to diagnose due to the similarity in clinical and pathological presentations. In virtually all cases reported in the literature, an abnormal karyotype has been reported to be the most important prognostic factor. We proposed that in cases with diagnostic ambiguity, an abnormal karyotype can help favor SEBVTCL over EBV+ HLH.